FAOAI
CRSP icon

Fund Advisors of America Inc’s CRISPR Therapeutics CRSP Stock Holding History

Fund Advisors of America Inc’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Sell
5,371
-1,171
-18% -$61.7K 0.27% 87
2026
Q1 		$311K Sell
6,542
-1,041
-14% -$54.9K 0.32% 77
2025
Q4 		$398K Buy
+7,583
New +$454K 0.36% 72

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fund Advisors of America Inc's CRSP Position: Q2 2026 in Review

Fund Advisors of America Inc reduced its CRISPR Therapeutics (CRSP) stake by 18% in Q2 2026, selling an estimated $61.7K and leaving 5,371 shares worth $293K. The position accounts for 0.27% of the portfolio, ranked #87.

Fund Advisors of America Inc first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $398K in Q4 2025. 490 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Fund Advisors of America Inc held 5,371 shares of CRISPR Therapeutics worth $293K as of Q2 2026.
  • Fund Advisors of America Inc sold 1,171 CRISPR Therapeutics shares in Q2 2026, an estimated $61.7K.
  • CRISPR Therapeutics made up 0.27% of Fund Advisors of America Inc's portfolio in Q2 2026, its #87 holding.
  • Fund Advisors of America Inc first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Fund Advisors of America Inc's CRISPR Therapeutics position peaked at $398K in Q4 2025.
  • 490 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Fund Advisors of America Inc's 13F filing for Q2 2026, filed 11 Aug 2026.